Skip to Content

Cardinal Health Inc CAH

Rating as of

Morningstar’s Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat




Cardinal Results Cut Against the Grain of Oligopoly Peer Trends; Mix and Contracting Likely Culprits

Soo Romanoff Equity Analyst

Analyst Note

| Soo Romanoff |

Cardinal Health reported fourth-quarter normalized EPS of $1.04 based on better cost management, partially offset by revenue decline. Despite the beat, management’s outlook was relatively pessimistic compared with its two closest peers, McKesson and AmerisourceBergen, which we attribute to the company’s increasing ambulatory mix and negotiated (client) contract terms. As the industry has evolved toward specialty drugs, Cardinal Health has lagged peers in capturing share and has focused on ambulatory clients, enabled through its medical acquisitions. Shelter-in-place orders as a result of the coronavirus pandemic have affected this subsegment most, as patients have deferred or canceled elective procedures and provider visits. This was likely exacerbated with the pull-through of commodity drugs and personal protective equipment volumes in the third quarter along with incremental costs to secure these high-demand items. We expect this dynamic to continue based on the assumed slow recovery. The timing of the pandemic has also been tough on the company, as it recently recovered from a disastrous gown contamination mishap. Despite these adverse trends, we do not anticipate a notable swing in its leading position unless the company is unable to recover for an extended period. The three largest distributors have secured roughly a third of the pharmaceutical market. We will continue to monitor the market trends and maintain our narrow moat and fair value estimate of $60 per share.

Read Full Analysis

Company Profile

Business Description

Cardinal Health Inc is the third- largest global logistics provider engaged in wholesale pharmaceutical and medical products. Similar to the other two peers, the company has evolved over time and has become entrenched in the sourcing and distribution of brand-name and generic pharmaceuticals and related services to hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices. Through acquisitions, Cardinal Health has the ability to manufacture commodity products and certain medical devices.

7000 Cardinal Place
Dublin, OH, 43017
T +1 614 757-5000
Sector Healthcare
Industry Medical Distribution
Most Recent Earnings Jun 30, 2020
Fiscal Year End Jun 30, 2020
Stock Type High Yield
Employees 48,000